Broadway Wealth Solutions Inc. Invests $274,000 in IQVIA Holdings Inc. (NYSE:IQV)

Broadway Wealth Solutions Inc. bought a new position in IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,396 shares of the medical research company’s stock, valued at approximately $274,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Synergy Asset Management LLC bought a new position in IQVIA in the fourth quarter valued at $33,000. Lee Danner & Bass Inc. acquired a new stake in shares of IQVIA in the fourth quarter valued at approximately $44,000. Zions Bancorporation N.A. boosted its stake in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after acquiring an additional 85 shares during the period. Versant Capital Management Inc increased its holdings in shares of IQVIA by 46.0% during the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after acquiring an additional 93 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in IQVIA during the 4th quarter valued at $60,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

IQV has been the topic of several research analyst reports. JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. Stephens initiated coverage on IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective for the company. Citigroup dropped their price target on IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. Finally, William Blair reissued an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Stock Performance

Shares of IQVIA stock opened at $179.40 on Friday. The stock has a market cap of $31.63 billion, a price-to-earnings ratio of 23.92, a P/E/G ratio of 1.99 and a beta of 1.50. The company’s fifty day moving average is $193.55 and its 200 day moving average is $206.91. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a twelve month low of $176.74 and a twelve month high of $253.84.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.